ReviewFEMS microbiology reviews2018
Secondary metabolite production and the safety of industrially important members of the Bacillus subtilis group.
Review in FEMS microbiology reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed.
- Secondary Metabolite Biosynthesis and Regulatory Role of Sucrose inMicroorganisms · 2026Review
- A review of the iron requirements and its determination in commercial poultry.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Review
- Systematic Categorization and Functional Diversity of Secondary Metabolites from Bacillus spp.: A Review.Probiotics and antimicrobial proteins · 2026Review
- Phenotypic and Genomic Analysis of Swine-DerivedAnimals : an open access journal from MDPI · 2026Article
- Exploration of Length and Hydrophobicity Requirements for Optimal α-Amylase Secretion in Bacillus subtilis Based on Rational Design.Microbial biotechnology · 2026Article
- Membrane remodelling mediates lipopeptide-induced immunity in Arabidopsis.Nature plants · 2026Article
- Genome and antimicrobial compounds analysis of Bacillus subtilis M51 as a potential biocontrol agent against Fusarium oxysporum.BMC genomics · 2026Article
- Genome sequence ofMicrobiology resource announcements · 2026Article
- Multifunctional Bioactivity ofCurrent issues in molecular biology · 2026Article
- Whole genome analysis ofFrontiers in microbiology · 2026Article
- Extraction and Characterization of Iturin A as a Key Factor in the Antagonism ofRecent patents on biotechnology · 2026Article
- Genomic insights and evaluation ofFrontiers in cellular and infection microbiology · 2026Article
- Culture-Dependent Bioprospecting of Halophilic Microorganisms from Portuguese Salterns.Microorganisms · 2025Article
- The Mechanisms ofMicroorganisms · 2025Review
- Highly efficient genome editing inSynthetic and systems biotechnology · 2025Article
- Article
- Article
- In Vitro Evaluation of HalotolerantMicroorganisms · 2025Article
- Bacterial community profile of three Ethiopian hot springs based on 16S rRNA gene nanopore sequencing.Scientific reports · 2025Article
- In Silico and In Vitro Characterization ofFoods (Basel, Switzerland) · 2025Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Members of the 'Bacillus subtilis group' include some of the most commercially important bacteria, used for the production of a wide range of industrial enzymes and fine biochemicals. Increasingly, group members have been developed for use as animal feed enhancers and antifungal biocontrol agents. The group has long been recognised to produce a range of secondary metabolites and, despite their long history of safe usage, this has resulted in an increased focus on their safety. Traditional methods used to detect the production of secondary metabolites and other potentially harmful compounds have relied on phenotypic tests. Such approaches are time consuming and, in some cases, lack specificity. Nowadays, accessibility to genome data and associated bioinformatical tools provides a powerful means for identifying gene clusters associated with the synthesis of secondary metabolites. This review focuses primarily on well-characterised strains of B. subtilis and B. licheniformis and their synthesis of non-ribosomally synthesised peptides and polyketides. Where known, the activities and toxicities of their secondary metabolites are discussed, together with the limitations of assays currently used to assess their toxicity. Finally, the regulatory framework under which such strains are authorised for use in the production of food and feed enzymes is also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.